1. Turkey Stocks

  2. •

    Health services

  3. •

    Hospital/Nursing management
Nasmed Ozel Saglik Hizmetleri Ticaret A.S.

Nasmed Ozel Saglik Hizmetleri Ticaret A.S.

BBIST:EGEPO
4.24
TRY
-0.14
(-3.20%)
-0.12EPS
9.18BMarket Cap
Nasmed Ozel Saglik Hizmetleri Ticaret A.S.
BIST:EGEPO
(Istanbul Exchange)

Recent

price

4.24

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
TRY
0.14
0.16
0.23
0.34
1
1.78
2.64
2.69
3.27
Revenue per Share
0.02
0.01
0.07
0.03
-0.29
0.27
-0.06
0.01
-0.12
Basic EPS, GAAP
0.03
0.04
0.01
-0.16
-0.24
-0.09
0.27
-0.08
0.29
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.17
0.19
0.25
0.59
1.79
2.84
3.65
3.82
4.32
Book Value per Share
0.16
0.16
0.23
0.56
1.64
2.62
3.36
3.5
3.94
Tangible Book Value per Share
500
500
500
500
500
500
500
500
500
Basic Weighted Avg Shares
71
80
115
170
499
891
1,321
1,346
1,634
Sales/Revenue/Turnover
17.61
13.83
24.93
14
-4.95
3.28
-1.51
4.89
5.85
Operating Margin (%)
1
1
9
12
77
115
175
172
174
Depreciation Expense
8
6
33
17
-146
133
-30
3
-59
Net Income, GAAP
2.75
15.91
1.35
4.68
- -
2.99
- -
86.73
249.98
Effective Tax Rate (%)
11.66
7.48
28.75
10.27
-29.35
14.88
-2.28
0.2
-3.64
Profit Margin (%)
3
6
12
47
81
79
147
162
247
Working Capital
36
46
50
36
156
121
66
38
5
LT Debt
87
93
126
293
893
1,418
1,824
1,908
2,161
Total Equity
- -
6.95
22.16
9.04
- -
3.33
- -
0.39
-7.07
Return on Invested Capital (%)
- -
7.16
23.39
8.66
- -
12.58
- -
0.23
-4.6
Return on Capital (%)
- -
6.61
30.15
8.33
-24.68
11.47
-1.86
0.14
-3.14
Return on Common Equity (%)

Capital Structure

TRY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2
6
35
LT Borrowings
- -
- -
- -
LT Finance Leases
38
37
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
500
500
500
Market Capitalization
4,095
6,865
9,175

Working Capital

TRY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
364
461
537
Cash, Cash Equivalents & STI
165
194
255
Accounts Receivable, Net
162
236
243
Inventories
10
12
14
Total Current Liabilities
202
262
290
Payables & Accruals
- -
- -
- -
ST Debt
2
6
35
Deferred Revenue
- -
- -
- -

Growth Rates

TRY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
86.03%
4.57%
Free Cash Flow
- -
-521.06%
-128.06%
Net Income, GAAP
- -
-281.74%
-108.83%
Sales/Revenue/Turnover
- -
74.15%
1.88%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TRY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
288
270
332
296
1,321
2025
376
380
325
384
1,346
2026
438
488
- -
- -
- -

Quarterly Earnings Per Share

TRY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.06
- -
0.19
-0.13
-0.06
2025
- -
- -
-0.02
0.03
0.01
2026
0.07
-0.2
- -
- -
- -

Quarterly Dividends Per Share

TRY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Apollo Hospitals Enterprise Limited (NSE:APOLLOHOSP)
Max Healthcare Institute Ltd (NSE:MAXHEALTH)
Fortis Healthcare Ltd. (NSE:FORTIS)
Bangkok Dusit Medical Services Public Co. Ltd. (SET:BDMS)
Yatharth Hospital and Trauma Care Services Limited (NSE:YATHARTH)
HCA Healthcare, Inc. (NYSE:HCA)
Business
Nasmed Ozel Saglik Hizmetleri Ticaret A.S. is a Turkey-based healthcare services company that owns and operates private general and specialized hospitals under the Egepol Hospitals (Egepol Hastaneleri) brand. Founded in 2003 and headquartered in Izmir, Turkey, the company provides inpatient, outpatient, diagnostic, surgical, and emergency medical treatments across its hospital network, which comprises Egepol Hospital, Egepol Surgical Hospital, and Egepol International Hospital. Nasmed delivers systematic medical services across a broad spectrum of clinical specialties, including general surgery; cardiovascular surgery; brain and neurosurgery; orthopedics and traumatology; obstetrics and gynecology; pediatrics and pediatric subspecialties; internal medicine; cardiology; neurology; pulmonology; gastroenterology; dermatology; psychiatry; physical therapy and rehabilitation; ophthalmology; otorhinolaryngology; urology; and plastic, reconstructive, and aesthetic surgery. Its clinical infrastructure also provides specialized critical care through adult, neonatal, and cardiovascular intensive care units; 24/7 emergency medical response; comprehensive diagnostic imaging and radiology services, including magnetic resonance imaging, computed tomography, ultrasonography, and digital radiography; accredited clinical laboratory and pathology testing; oral and dental health treatments; nutritional counseling; and comprehensive preventative check-up packages. Serving local, regional, and international patient bases, the company caters to private health insurance policyholders, corporate partners, social security beneficiaries, and global medical tourists. In recent strategic developments, Nasmed completed the multi-phase technological renovation and facility modernization of its hospital complex, bringing its operational infrastructure to full capacity at 325 licensed hospital beds. To strengthen its financial position and support corporate growth, the company completed a significant bonus share capital increase, raising its paid-in capital from TRY 125 million to TRY 500 million through internal inflation adjustment reserves. In addition, Nasmed has accelerated its international healthcare tourism expansion by deploying targeted marketing programs and multilingual patient coordination networks across Europe and the Middle East, with a specific operational focus on obesity surgery, aesthetic procedures, dental care, and advanced orthopedic interventions.